1
|
Abstract
Although several strategies have been developed to support medical students during their studies in order to prevent burnout, depression and suicide, not all of them are equally effective. Simulation is an interesting strategy: it gives students the tools to detect and intervene in signs of distress in their colleagues, and helps them break the barrier of silence in the face of psychological distress.
Collapse
Affiliation(s)
- Nathalie Nadon
- Centre hospitalier de l'université de Montréal, 1000 rue Saint-Denis, Montréal, QC H2X 0A9, Canada.
| | - Pierre Laramée
- Centre hospitalier de l'université de Montréal, 1000 rue Saint-Denis, Montréal, QC H2X 0A9, Canada
| |
Collapse
|
2
|
Whalley D, Crawford SR, Laramée P, Higuchi S, Hao W, Kim SG, Luquiens A, Aubin HJ. Cultural Adaptation of the Alcohol Quality of Life Scale for Use in Japan, China, and Korea. Value Health 2014; 17:A462. [PMID: 27201299 DOI: 10.1016/j.jval.2014.08.1282] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/05/2023]
Affiliation(s)
- D Whalley
- RTI Health Solutions, Manchester, UK
| | | | - P Laramée
- Lundbeck S. A. S., Issy-les-Moulineaux cedex, France
| | - S Higuchi
- National Hospital Organization Kurihama Medical and Addiction Center, Yokosuka, Japan
| | - W Hao
- Second Xiangya Hospital of Central South University, Changsha, China
| | - S G Kim
- Pusan National University, Yangsan, South Korea
| | - A Luquiens
- Hôpital Paul Brousse, INSERM 669, Université Paris-Sud, Villejuif, France
| | - H J Aubin
- Hôpital Paul Brousse, INSERM 669, Université Paris-Sud, Villejuif, France
| |
Collapse
|
3
|
Whalley D, Luquiens A, Crawford SR, Laramée P, Doward L, Price M, Hawken NA, Dorey J, Owens L, Llorca PM, Falissard B, Aubin HJ. The Patient Experience of Alcohol use Disorder. Value Health 2014; 17:A462. [PMID: 27201301 DOI: 10.1016/j.jval.2014.08.1283] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/05/2023]
Affiliation(s)
- D Whalley
- RTI Health Solutions, Manchester, UK
| | - A Luquiens
- Hôpital Paul Brousse, INSERM 669, Université Paris-Sud, Villejuif, France
| | | | - P Laramée
- Lundbeck S. A. S., Issy-les-Moulineaux cedex, France
| | - L Doward
- RTI Health Solutions, Manchester, UK
| | - M Price
- (4)RTI Health Solutions, Research Triangle Park, NC, USA
| | - N A Hawken
- Creativ-Ceutical, Luxembourg, Luxembourg
| | - J Dorey
- Creativ-Ceutical USA, Chicago, IL, USA
| | - L Owens
- Institute of Translational Medicine, University of Liverpool, Liverpool, UK
| | - P M Llorca
- Centre Hospitalier Universitaire de Clermont-Ferrand, Clermont-Ferrand, France
| | - B Falissard
- Hôpital Paul Brousse, INSERM 669, Université Paris-Sud, Villejuif, France
| | - H J Aubin
- Hôpital Paul Brousse, INSERM 669, Université Paris-Sud, Villejuif, France
| |
Collapse
|
4
|
Pellissier A, Larochelle E, Krsticevic L, Baron E, Le V, Roy A, Deragon A, Cote M, Laramée P, Leclerc S, Garcia D, Tournoux F. CARDIAC REMODELING IN RUGBY AND FOOTBALL LINE PLAYERS IS ASSOCIATED WITH BOTH SUBCLINICAL SYSTOLIC AND DIASTOLIC DYSFUNCTION. Can J Cardiol 2014. [DOI: 10.1016/j.cjca.2014.07.163] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022] Open
|
5
|
Théroux P, Alexander J, Dupuis J, Pesant Y, Gervais P, Grandmont D, Kouz S, Laramée P, Huynh T, Barr E, Sax FL. Upstream use of tirofiban in patients admitted for an acute coronary syndrome in hospitals with or without facilities for invasive management. PRISM-PLUS Investigators. Am J Cardiol 2001; 87:375-80. [PMID: 11179517 DOI: 10.1016/s0002-9149(00)01386-2] [Citation(s) in RCA: 19] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
Abstract
Management and prognosis of acute coronary syndromes may be influenced by the availability of catheterization facilities at admitting hospitals. Treatment effects of tirofiban were examined in a Canadian cohort of 834 patients enrolled in the Canadian Platelet Receptor Inhibition in Ischemic Syndrome Management in Patients Limited by Unstable Signs and Symptoms (PRISM-PLUS) trial according to admission into hospitals without (n = 322) or with catheterization facilities (n = 512). Hospital transfers for cardiac catheterization were facilitated using preexisting networks accelerated for the purposes of the protocol. In hospitals without facilities, the relative risks for occurrence of death, infarction, or refractory ischemia among patients receiving tirofiban plus heparin compared with heparin alone were 0.52 at 7 days (p = 0.02), 0.59 at 30 days (p = 0.03), and 0.70 at 180 days (p = 0.09); and for death or infarction, 0.32 (p = 0.02), 0.46 (p = 0.04,) and 0.51 (p = 0.03), respectively. Benefit was seen regardless of transfer status, with no statistically significant interaction between treatment, hospital type, and catheterization for any end point at any time point. The incidence of Thrombolysis In Infarction defined major bleeding with respect to therapy was not significantly different between hospital types. Thus, upstream treatment with tirofiban plus heparin confers clinical benefits in unstable angina and/or non-ST-segment elevation infarction patients regardless of whether initial presentation is to a hospital without catheterization facilities or to a hospital with such facilities.
Collapse
Affiliation(s)
- P Théroux
- Montreal Heart Institute, Quebec, Canada.
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
6
|
Cohen M, Théroux P, Weber S, Laramée P, Huynh T, Borzak S, Diodati JG, Squire IB, Deckelbaum LI, Thornton AR, Harris KE, Sax FL, Lo MW, White HD. Combination therapy with tirofiban and enoxaparin in acute coronary syndromes. Int J Cardiol 1999; 71:273-81. [PMID: 10636535 DOI: 10.1016/s0167-5273(99)00171-0] [Citation(s) in RCA: 63] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
Abstract
BACKGROUND Tirofiban, an intravenous glycoprotein IIb/IIIa antagonist, and enoxaparin, a low molecular weight heparin, have each been shown to be effective at reducing cardiac ischemic events compared to unfractionated heparin alone in separate trials of patients with unstable angina and non-Q-wave myocardial infarction. The combination of these agents may offer further therapeutic benefit. MATERIALS AND METHODS Fifty-five patients with non-Q-wave myocardial infarction were randomized to receive double-blind treatment with tirofiban (0.1 microgram/kg/min i.v.) for 48-108 h coadministered with either enoxaparin (1 mg/kg sc q 12 h) (n=26) or unfractionated heparin (i.v. adjusted to activated partial-thromboplastin time) (n=27) to evaluate pharmacokinetics, pharmacodynamics, and safety. The primary objective of the study was to investigate the effect of unfractionated heparin versus enoxaparin on the plasma clearance of tirofiban. RESULTS Coadministration of tirofiban and enoxaparin was generally well tolerated. Plasma clearance of tirofiban was 176.7+/-59.8 and 187.5+/-81.8 ml/min, respectively, for enoxaparin and unfractionated heparin-treated patients (P=NS). The mean difference was well within the prespecified criterion for comparability. Administration of tirofiban with enoxaparin vs. unfractionated heparin resulted in lesser variability and a trend towards greater inhibition of platelet aggregation using 5 microM adenosine phosphate agonist. More patients achieved target inhibition of platelet aggregation >70% in the tirofiban and enoxaparin group (84% vs. 65%, P=0.19). Median bleeding time was 21 min for tirofiban and enoxaparin vs. > or =30 min for tirofiban and unfractionated heparin (P=NS). For a given level of inhibition of platelet aggregation, bleeding time was less prolonged with tirofiban and enoxaparin than tirofiban and unfractionated heparin (adjusted mean bleeding time 19.6 vs. 24.9 min, P=0.02). Tirofiban plasma concentration and clearance were comparable whether coadministered with enoxaparin or unfractionated heparin. There were no major or minor bleeding events in either group by the TIMI criteria. INTERPRETATION The more consistent inhibition of platelet aggregation and lower adjusted bleeding time of tirofiban and enoxaparin vs. tirofiban and unfractionated heparin support the therapeutic potential of combining these two agents. These data from the first clinical report of coadministration of a glycoprotein IIb/IIIa receptor antagonist and a low molecular weight heparin are consistent with prior data which show differential pharmacodynamic effects of enoxaparin and unfractionated heparin on platelet aggregation.
Collapse
Affiliation(s)
- M Cohen
- Hahnemann University Hospital, Philadelphia, PA, USA
| | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
7
|
Huckell VF, Bernstein V, Cairns JA, Crowell R, Dagenais GR, Higginson LA, Isserow S, Laramée P, Liu P, McCans JL, Orchard RC, Prewitt R, Quinn BP, Samson M, Turazza F, Warnica JW, Wielgosz A. Angiotensin-converting enzyme inhibition in myocardial infarction--Part 1: Clinical data. Can J Cardiol 1997; 13:161-9. [PMID: 9070168] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/03/2023] Open
Abstract
There is an increasing body of clinical trial evidence to support the use of angiotensin-converting enzyme (ACE) inhibitors in the management of patients following myocardial infarction (MI). Enthusiasm for the use of ACE inhibitors in the acute phase of MI had previously been tempered by the adverse results of an early trial. However, exciting new information is available from several large, randomized studies that has not only quelled those initial concerns but also attests to the efficacy of using this class of medication in the first 24 h after an acute MI. A Canadian National Opinion Leader Symposium was held in November 1995 to review the results of the major ACE inhibitor clinical trials and to discuss key issues and controversies surrounding their use in acute MI. The focus of this paper, the first of two parts, is on the results of the major ACE inhibitor clinical trials.
Collapse
|
8
|
Huckell VF, Bernstein V, Crowell R, Dagenais GR, Higginson LA, Isserow S, Laramée P, Liu P, McCans JL, Orchard RC, Prewitt R, Quinn BP, Samson M, Turazza F, Warnica JW, Wielgosz A. Angiotensin-converting enzyme inhibition in myocardial infarction--Part 2: Clinical issues and controversies. Can J Cardiol 1997; 13:173-82. [PMID: 9070169] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/03/2023] Open
Abstract
Over the past 10 years, several clinical studies have concluded that, in patients already receiving conventional therapies, angiotensin-converting enzyme (ACE) inhibitors further reduce the risk of death following myocardial infarction (MI). Post-MI ACE inhibitors have proven to be effective as long term therapy in high risk patients as well as when used for much shorter periods in a broad patient population. However, while considerable mortality data have been collected, the effects of ACE inhibitors post-MI on other cardiovascular outcomes have not been as well documented. In addition, a number of issues regarding the most effective use of these agents remain unresolved. This paper, the second of two parts, focuses on the clinical issues and controversies surrounding the use of ACE inhibitors following acute MI. The effects of ACE inhibitors on the outcomes of sudden death, nonsudden death, recurrent angina, mitral regurgitation and left ventricular dysfunction are reviewed and potential mechanisms of action are proposed. In addition, ACE inhibitor therapy is discussed in terms of patient selection criteria, choice of agent, optimal dosing regimen, concomitant use of other therapies and relative costs of treatment. Finally, potential mechanisms of action of ACE inhibitors are proposed for each of the outcomes examined.
Collapse
|
9
|
Doucet S, Gagnon RM, Laramée P, Beaudet R. Late coronary aneurysm formation following coronary angioplasty. Can J Cardiol 1990; 6:399-401. [PMID: 2276076] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/31/2022] Open
Abstract
In a 38-year-old man with recurrent chest pain 14 months following percutaneous transluminal coronary angioplasty (PTCA) of the left anterior descending coronary artery, two aneurysms were noted at previous PTCA sites without evidence of restenosis. Although the precise mechanism of formation of these aneurysms is not known, it is possible that medial dissection and weakening of the artery provoked aneurysm formation.
Collapse
Affiliation(s)
- S Doucet
- Cardiology and Cardiothoracic Division, Notre-Dame Hospital, University of Montreal, Quebec
| | | | | | | |
Collapse
|
10
|
Gagnon RM, Morissette M, Laramée P, Dumont G, Sestier F, Leclerc G, Goudreau E. Efficacy of delayed percutaneous transluminal coronary angioplasty after intravenous use of streptokinase in myocardial infarction. CMAJ 1988; 139:405-8. [PMID: 2970290 PMCID: PMC1268156] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/03/2023] Open
Abstract
Between June 1984 and December 1986, 35 patients with acute myocardial infarction received streptokinase intravenously within 3 hours after the beginning of chest pain and underwent percutaneous transluminal coronary angioplasty (PTCA) either immediately (in 2 cases) or 1 to 19 (mean 4.4) days later (in 33). The rate of successful PTCA was 89%. Reocclusion occurred in one patient. The mean percentage of stenosis decreased from 86% to 11%. The mean trans-stenotic gradient was reduced from 41 to 11 mm Hg. The results suggest that in patients whose condition is stable, PTCA performed a few days after thrombolysis is a valuable alternative to more aggressive treatment with immediate PTCA.
Collapse
|
11
|
Laramée P. [Intravenous thrombolysis in acute myocardial infarction]. Union Med Can 1988; 117:276-8. [PMID: 3188285] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 01/04/2023]
|
12
|
Abstract
Kawasaki disease is a mucocutaneous lymph node syndrome with important cardiovascular complications that usually afflicts young children. We describe a 31-year-old woman who developed transient heart failure during the acute phase of Kawasaki disease. The diagnosis was supported by the presence of all six criteria of the disease: fever, conjunctivitis, strawberry tongue, cervical lymphadenopathies, truncal exanthem, and periungual membranous desquamation. Related clinical and laboratory findings included heart failure, arthralgias, transverse nail grooves, thrombocytosis, and elevated serum glutamic oxaloacetic transaminase (SGOT), serum glutamic pyruvic transaminase (SGPT), and bilirubin. Alternative diagnoses were excluded. During her acute febrile illness, the patient developed tachycardia, hypotension, pulmonary rales, S3 gallop, and hepatojugular reflux. The chest roentgenogram showed new Kerley A and B lines. A first-pass isotopic ventriculography showed diffuse hypokinesia and decreased ventricular ejection fractions; spontaneous recovery occurred after a few days. A coronarography performed two months later showed no aneurysmal dilatation. Kawasaki disease is a cause, albeit rare, of myocardial dysfunction in the adult human, and should be sought for actively in a patient with heart failure during the course of an acute febrile illness, associated with mucocutaneous changes.
Collapse
|